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The  BCL1  tumor  is  a  B  cell  neoplasm  that  causes  massive  splenomegaly  and 
leukemia in  BALB/c  (Ig-1 a)  mice (1).  The tumor cells bear IgM and  IgD on their 
surface and are phenotypically and functionally analogous to immature B cells  (2). 
When  mice from an allotype-congenic strain,  C.B-20  (Ig-l~),  are injected with  10  °- 
107 BCL1 cells,  they are resistant  to tumor growth  (3).  These mice generate T  cells 
that can adoptively transfer tumor immunity to sublethally irradiated C.B-20 recip- 
ients. Upon in vitro rechallenge of their spleen cells, cytotoxic effector cell activity is 
generated  that  is  directed  against  antigens  on  BALB/c  lymphoblast target cells as 
well as on BCLt cells (3). 
Little information is available on the role of cytotoxic T  cells in regulating B cell 
neoplasms. Abbas et al. (4) described effector cells that inhibited MOPC 315 secretion 
in  vitro.  These cells were phenotypically characteristic of cytotoxic T  lymphocytes 
(CTL)) However, their specifcity was directed against the myeloma's ligand,  trini- 
trophenol,  rather  than  against  immunoglobulin  (Ig)  itself.  Most  CTL activity that 
has been described  is directed  against  viral antigens,  minor H  antigens,  or haptens 
covalently coupled to cell membranes (5, 6). With the exception of trinitrophenylated 
proteins (7-9), CTL apparently display specificity for integral membrane proteins or 
molecules that  can  fuse with  the plasma membrane  (10).  Accordingly, CTL could 
potentially be generated against surface Ig (sIg) determinants.  In this regard, Rolink 
et  al.  (11)  generated CTL using allotype congenic strains.  However, the antigen(s) 
recognized by their effector cells were detected on a  T  cell tumor as well as both T 
and B lymphoblasts and presumably represent minor H  antigens. 
In this report we have determined the specifity of C.B-20 anti-BALB/c (anti-Ig H) 
cytotoxic effector cells as well as the tissue distribution of the antigen(s) recognized by 
these effector cells.  The simplest  interpretation  of our data is that  the effector cells 
recognize  either  the  constant  portion  of the  #  and/or  8  heavy  chain  on  Ig  or  a 
molecule coordinately expressed on sIg  + cells. 
Materials and Methods 
Mice.  Mice were initially obtained from Dr. Michael  Potter at the National Institute of 
Health (National Cancer Institute contract N01-CB094326).  Mice were subsequently bred in 
our laboratories at the University of Texas Health Science Center. 
* Supported by grants CA-23115, AI-12789, and CA-28149 from the National Institutes of Health. 
l Abbreviations used in this paper." Con A, concanavalin A; CTL, cytotoxic T cells; FACS, fluorescence- 
activated cell sorter; FITC, fluoresceinated; LPS, lipopolysaccharide; NRIg, normal rabbit Ig; RAMIg, 
rabbit anti-mouse Ig; sIg,  surface Ig. 
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Generation of CTL.  Mice were inoculated with 3 ×  10  v spleen cells intraperitoneally.  1-6 mo 
later,  spleens  were  removed  from  these  injected  mice  and  cultured  in  vitro  as  previously 
described (12) in order to generate cytotoxic effector cells. 
Preparation of Target Cells.  Coneanavalin A  (Con A) lymphoblast targets were prepared as 
previously described  (12).  Lipopolysaccharide (LPS)  lymphoblast targets were generated by 
culturing spleen cells at a concentration of 4 ×  106 cells/ml in RPMI 1640 with 10% fetal calf 
serum for 2 d, at which time  100/zg of LPS was added. The cells were then cultured  for an 
additional 3 d before use. 
Splenic T  cells were prepared by passing spleen cells over nylon wool columns. The T  cells 
were then cultured for 3 d in the presence of 5/zg/ml of Con A together with adherent cells. 
Splenic B cells were prepared by treating spleen cells with monoclonal anti-Thy-l.2 antibody 
(New England Nuclear, Boston, Mass.)  and complement. The surviving cells were cultured for 
3 d in the presence of LPS. On the day of assay, target cells were labeled with ~aehromium and 
centrifuged through an Isolymph solution  (Gallard-Schlesinger Chemical  Mfg. Corp., Carle 
Place, N. Y.) to remove nonviable cells. 
Analysis of Thy-I + and Ig  + Cells.  In some experiments,  target  cells  were analyzed  for the 
percentage of Ig  + cells by incubating the suspensions with fluoresceinated (FITC) rabbit anti- 
mouse Ig (F-RAMIg) (N. L. Cappel Laboratories, Cochranville, Pa.). 
Thy-1 + cells were detected by incubation with monoclonal anti-Thy-l.2, followed by the F- 
RAMIg reagent. Similarly, aliquots were stained with F-RAMIg alone. The percentage of anti- 
Thy-1  + cells was thus calculated by subtraction. 
Tumor Cells.  BCL1 cells were originally obtained from Dr. Sam Strober, Stanford University 
Medical  Center,  Palo Alto, Calif.  MOPC  315  was kindly provided by Dr.  Richard  Lynch, 
Washington University Medical School, St.  Louis, Mo. MOPC 245, MOPC 300, TEPC  183, 
and P1798 were obtained from Dr. Michael Potter. MOPC 104E was provided for by Dr. Mel 
Bosma, Institute for Cancer Research, Philadelphia,  Pa., and TEPC  15 was provided by Dr. 
John Cambier,  Duke University, Durham, N. C. BCL1 ×  X63 is a  hybridoma line resulting 
from the fusion of P3 ×  X63Ag8 (abbreviated X63) to BCL1 (13). 
Assay for CTL.  The assay for cytotoxic effector cell activity has been described previously 
(12).  Net release of isotope represents  the percent  release  of isotope from target cells  in the 
presence of immune cells minus the percent release  of isotope from target cells in the presence 
of control cells. Control cells represent cells from cultures lacking stimulator cells. The release 
of isotope from target cells in the presence of control cells ranged from 20 to 35%. 
Indirect Fluorescence Analysis Using the Fluorescence-activated Cell Sorter (FACS).  The in vivo (1) 
and in vitro (14) lines of BCL1 cells as well as the BCL1 ×  X63 hybridoma cells were stained 
with an affinity-purified polyvalent RAMIg or normal rabbit Ig (NRIg) control followed by 
FITC goat anti-rabbit Ig. Cells were analyzed on the FACS (B-D FACS Systems, Sunnyvale, 
Calif.)  as described previously (15). 
Results 
Mice Challenged  with Tumor Cells from an Ig H  Chain Congenic Strain Generate Anti-Tumor 
CTL.  We have previously reported  (3)  that  BALB/e  (Ig-1 a)  mice inoculated  with 
106 or 107 BCL1 tumor cells die from the tumor after ~8 wk. On the other hand, mice 
from an Ig H  chain congenic strain, C.B-20 (Ig-1 b), are resistant to the same inoculum 
of BCL1 cells. T  cells from the spleens of these tumor-rejector mice adoptik,  ely transfer 
protection to irradiated C.B-20 animals. 
When spleen cells from C.B-20 tumor-rejector mice were tested for their cytotoxic 
potential, they did not display activity against BCL1 or BALB/c lymphoblasts  (data 
not shown).  However, their spleen  cells could be sensitized  against  either irradiated 
BCL1 or BALB/c cells in a secondary in vitro culture system so that cytotoxic activity 
was generated  against  both BCLx and BALB/c target cells  (Table  I). Because these 
effector cells  could be responsible  for adoptive  transfer  of tumor immunity  against JAMES FORMAN, RICHARD CIAVARRA, AND ELLEN  S. VITETrA 
TABLE I 
Ability of C.B-20 Mice That Have Rejected BCLI Cells to Generate Effector Cell Activity 
1359 
Cells  Net isotope release at E:T 
Effectors  Stimulators  Targets  100:1  50:1  10:1 
C.B-20*  BCL1  BCL1  24.3  17.6  4.6 
Anti-BCL~  BALB/c:~  19,7  18.7  5.4 
BALB/c  BCLI  9.6  7.0  1.5 
BALB/c  7.1  7.2  -3.8 
* C.B-20 mice were inoculated  with  10  e BCLI cells 46 d earlier. Their spleen cells were 
removed and cultured with irradiated stimulator cells for 5 d in vitro before testing. 
LPS-stimulated splenic lymphoblasts. 
TABLE  II 
Cytotoxic Activity of CB-20 Anti-BALB/c Effector Cells 
Cells  Net isotope release at E/T 
Effectors  Targets*  100:1  50:1  10:1 
C.B-20 anti-BALB/c  BALB/c (Ig-l")~.  25.5  22.3  10.2 
C.B-20 (Ig-I b)  1.3  0.4  2.5 
B10.D2 (Ig-I b)  1.6  2.3  3.9 
(B6 × BALB/c)F~ (Ig-la/Ig-I b)  25.4  21.6  9.7 
BAB-14 (Ig-l"(v):Ig-lb(c))  0.2  1.0  1.3 
BALB/e anti-C.B-20  C.B-20  21.9  17.7  10.5 
BALB/c  0.8  -0.3  -  1.3 
B10.D2  16.9  10.6  4.5 
(B6 × BALB)F~  16. l  13.7  5.5 
BI0 (lg-I b)  -1.4  2.0  3.0 
BAB-14 anti-BALB/c  BALB/C  18.4  15.5  6.9 
* LPS-stimulated splenic lymphoblasts. 
:~ Genotype. 
BCLI, we further investigated the activity of effector cells generated against Ig heavy 
chain allotypic differences. 
Specificity  of CTL  Generated from the Sensitization  of lg H  Chain  Congenic Mice.  C.B-20 
mice were inoculated with BALB/c splenocytes. 2-6 mo later, their spleen cells were 
removed and the cells were cultured in vitro with irradiated BALB/c splenocytes for 
5  d,  at  which  time  the  cultures  were  assayed  for  cytotoxic  activity  against  LPS 
lymphoblasts. The data presented in Table II demonstrate that  these cells display a 
cytotoxic effect against BALB/c and  (BALB/c ×  B6)F1  (C57BL/6  is abbreviated as 
B6)  target cells. On the other hand, C.B-20 and B10.D2  (Ig-1 °)  target cells were not 
lysed. This latter result was expected because B 10,D2 has the same Ig H  chain linkage 
group  as C.B-20,  and  therefore should  not  be susceptible to lysis. Treatment  of the 
effector cells with  monoclonal anti-Thy-l.2 serum  and complement  abrogated their 
cytotoxic activity, indicating that the cytotoxic cells are T  cells (data not shown). 
BALB/c  anti-C.B-20  effector  cells were  also  treated  for  their  activity against  a 
similar panel of target cells. C.B-20, (BALB/c ×  B6)F1 and B10,D2 (H-2 d) target cells 
were killed by these effector cells. The lysis of B 10.D2 target cells presumably occurs 
because both C.B-20 and B10.D2  mice share the same alleles at their Ig H  chain loci. 1360  CYTOTOXIC  T  CELLS  SPECIFIC  FOR  Ig  +  CELLS 
The fact that H-2 congenic C57BL/10 (B10)  (H-2 b, Ig-l~  target cells were not lysed 
indicates that the cytotoxic effector cells are H-2 restricted. 
C.B-20 anti-BALB/c effector cells did not lyse BAB-14 target cells.  Because BAB- 
14 is a recombinant strain differing from C.B-20 at the  V but not the C region of Ig 
H  loci (16), this indicates that the specificity of the effector cells is directed against an 
antigen encoded for by a gene linked to the C region of the Ig H  chain linkage group. 
Further  evidence indicating  that  killer  cells  can  be  generated  against  an  antigen 
controlled  by  an  IgH  C  region-linked  gene  is  the  finding  that  BAB-14  animals 
sensitized  against  BALB/c  spleen  cells  generate  cytotoxic effector cells  that  lyse 
BALB/c targets (Table II). Thus, these data show that cytotoxic effector cells can be 
generated  across  the  Ig  H  chain  allotype barrier,  and  are  in  agreement  with  the 
previous report of Rolink et al.  (1 I). 
C.B-20 Anti-BALB/c  Effector  Cells Display Cross-reactive Lysis on  Target  Cells  Carrying 
Different Ig H Alleles.  The previous data indicate that C.B-20 and BALB/c mice can 
generate CTL with specificity for antigens controlled by genes that map to the Ig H 
chain linkage group. However, the specificity of these effector cells for other allotypes 
was not tested. 
The data in Table III indicate that C.B-20 anti-BALB/c effector cells display cross- 
reactive lysis on C.AL-20 target cells, which carry the Ig-1 d allele. Further, these cross- 
reactive effector cells can be generated by in vitro stimulation with either BALB/c or 
C.AL-20 stimulator cells.  In addition, C.B-20 effector cells also show cross-reactive 
lysis  on H-2-matched  DBA/2  (Ig-1 c)  targets.  These data suggest  that  either Ig-I a, 
Ig-I ~, and Ig-1 d strains express identical target  antigens;  or alternatively, there is a 
cross-reactive determinant  in  these three strains  in  addition  to unique specificities. 
Experiments are currently in progress to distinguish between these possibilities. 
Susceptibility  of BCLt  Cells  to  C.B-20  Anti-BALB/c  Effector  Cells.  We  previously 
demonstrated (3) that C.B-20 animals that had rejected a large inocula of BCL1 cells 
generated cytotoxic effector cells that lysed BCL1 and BALB/c target cells (Table I). 
In the following experiments, we ascertained whether effector cells produced by in 
vivo immunization of C.B-20  mice with  BALB/c spleen  cells would  also  generate 
effector cells that could recognize BCL1 target cells. 
The data in Table IV demonstrate that C.B-20 anti-BALB/c effector cells are able 
to lyse BCL1 target cells.  In this experiment, the in vivo BCL1 cells were obtained 
from the spleen, an organ that (in tumor-bearing animals) contains ~70% tumor cells 
(2). Because it is possible that BALB/c host cells rather than BCL1 cells are responsible 
TABLE  III 
Specificity of C.B-20 Anti-BALB/c Effector Cells 
Cells  Net release at E:T 
Effectors  Stimulators  Targets*  100:1  50:1  10:I 
C.B-20 anti-BALB/c  BALB/c  BALB/c (Ig-l")~  13.9  8.5  7.9 
C.AL-20 (Ig-I d)  16.8  11.2  4.7 
C.AL-20  BALB/c (lg-l")  17.5  11.0  1.4 
C.AL-20 (lg-1 a)  23,6  17.4  4.9 
BALB/c  DBA/2 (lg-1 c)  28,1  26.5  10.0 
* LPS-stimulated splenic lymphoblasts. 
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TABLE IV 
Susceptibility of BCL1 Cells to Anti-lg H Effector Cells 
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Cells  Net isotope release at E:T 
Effectors  Targets  100:1  50:1  10:1 
C.B-20 anti-BALB/c  BALB/c*  25.9  20.8  12.0 
C.B-20*  -3.5  -2.7  -1.5 
BCLI in vivo:~  20.9  19.0  9.0 
BCLa in vitro§  22.7  26.4  21.5 
BCL~ X X63]1  -4.3  -3.8  -2.9 
* LPS-stimulated splenic lymphoblasts. 
~: Spleen cells from a tumor-bearing animal. 
§ Line maintained by in vitro passage. 
[[ Hybridoma line (see text). 
for the lytic effect observed, we also tested an in vitro-adapted  BCL1 cell line (14). 
The data (Table IV)  demonstrate that these in vitro-cultured cells are sensitive to 
lysis. Thus, the anti-Ig H  region CTL do recognize antigenic determinants expressed 
by BCL1. 
BCL1 cells have been  fused to the myeloma line, X63.  This hybridoma secretes 
IgM, which bears the same idiotypic determinants expressed on the IgM and IgD of 
the parental BCLx tumor cell, as well as the IgGlk from the X63 cells (13). However, 
when this hybridoma line was tested for its sensitivity to lysis, no cytotoxic effect was 
observed (Table IV). 
These three BCL1 lines were also analyzed for cell surface Ig expression using the 
FACS. The data in Fig.  1 reveal that the two BCL1 lines contain a  large percentage 
of sIg  + cells (>50%), with a relatively heterogenous distribution of staining intensity. 
On the other hand, the BCLa hybridoma line contains very few sIg  + cells, and these 
cells stain with a relatively low intensity. 
Therefore, these results suggest that the expression of sIg is necessary for a  target 
cell to be sensitive to lysis by anti-Ig H  chain effector cells. 
Susceptibility  of Tumor  Lines  to Lysis  by Anti-Ig  H  Effector  Cells.  Because the BCLa 
(sIg  +)  B  cell  leukemia  was  killed  by  C.B-20  anti-BALB/c  effector cells,  we  next 
determined whether  other  BALB/c tumor  cells  also  expressed  the  target  antigen. 
Target  cells  included IgA-,  IgGa-, and  IgD-secreting  myeloma cells and  a  thymic 
lymphoma (P 1798). 
The data indicate that none of these tumor cells were sensitive to lysis by either 
C.B-20  anti-BALB/c or  BALB/e  anti-C.B-20  effector cells  (Table  V).  The  latter 
effector cells were used because three of the myelomas tested, MOPC  315,  MOPC 
300, and MOPC 245, are genotypically heterozygous at Ig-1; i.e., they were obtained 
from mice during backcrossing  to  generate the C.B-20  congenic line  (17,  18)  and 
could be sensitive to lysis as were (BALB/c ×  B6)F1 target cells (see Table II). The 
data also show that although the MOPC 315,  MOPC  300,  and P1798 cell lines are 
insensitive to lysis by C.B-20 anti-BALB/c effector cells, they are all sensitive to lysis 
by anti-H-2 CTL (B10.Q anti-BALB/c). 
If Ig is the target antigen, then it is possible that secreted Ig from myeloma cells 
could adsorb onto unlabeled cells in the effector cell population and block or inhibit 
lysis.  However, this alternative is unlikely. Thus, LPS induced B lymphoblasts and 1362  CYTOTOXIC  T  CELLS  SPECIFIC  FOR  Ig  +  CELLS 
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FIc.  1.  Analysis of slg on BCLI and BCLI  x  X63 hybridoma cells.  Cells were exposed to NRIg 
(solid  lines)  or RAMIg  (dashed  lines)  followed by FITC goat  anti-rabbit Ig. The cells were  then 
analyzed using the FACS. 
TABLE  V 
Susceptibility of Lyszs of BALB/c Tumor Cells to Anti-Ig H Effector Cells 
Cells  Myeloma  Net isotope relea.sc  at E:T 
Cell genotype  protein 
Eff¢ctors  Targets  allot  ype  100: I  50: I  10: I 
C.B-20 anti-BALB/c 
BALB/c anti-C,B-20 
BALB/c*  Ig-l" 
(BALB/c  X  B6)F2*  l¢-I°/(¢-I b 
C.B-20*  Ig-I b 
MOPC 315  lg-l~/lg-I t' 
MOPC 300  Ig- l~/Ig- I b 
MOPC 245  lg-I~/lg-I b 
P3 x  X63Ag8  lg-I ~ 
MOPC 315 
MOPC 300 
P1798  ,~e-/a 
BALB/c* 
24.8  20.7  16.4 
20.8  17.9  I 1.9 
--0.8  --0.6  --0.2 
lg-2  a  1.6  0.5  0.1 
lg-4  h  5.7  4.3  1.4 
Ig-4  b  3.7  2,5  0.5 
Ig-4  a  -0.8  --2,6  --4.3 
1.2 (25.7):~  0,4 (24.3)  0.8 (14.4) 
-0.8 (31.8)  -0,7 (27.5)  -0.5 (9,1) 
0.3 (36.1)  -0.5 (35.7)  -4.5 (22.6) 
25.3 (42.1)  25.9 (40.5)  17.1  (21.3) 
xt 
BALB/c*  0.8  -0.3  -1.3 
(BALB/c  X B6)FI*  16.1  13.7  5.5 
C.B-20*  21.9  17.7  10.5 
MOP(: 300  -2.6  -4.6  -7.0 
MOPC 245  -2. I  -3.7  -6.3 
MOPC 315  -1,4  -5.9  -10.0 
* I,PS-stimulated splenic lymphoblasts 
:~ Values in parentheses  represent  isotope release from target cells in the presence of anti-H-2 CTL (BIO.Q anti-BAI,B/c). JAMES FORMAN, RICHARD CIAVARRA, AND ELLEN S.  VITETTA  1363 
the in vitro BCLx cell line secretes Ig (19;  and unpublished  observations), but both 
are sensitive to lysis.  Furthermore, this type of mechanism for inhibition of lysis has 
not  been observed in  CTL assays.  For example, anti-viral  CTL lyse virus-infected 
target cells even though  such  targets release large quantities  of virus into  the assay 
media (20).  This inability of soluble antigen to inhibit effector CTL activity is most 
likely due  to  the  H-2  restriction  of T  cell  specificity where  shed  antigen  does  not 
apparently reassociate with H-2 class I antigens in in vitro assays (21). 
Table VI summarizes experiments that  include  all of the  tumor lines  that  were 
tested for the presence of the target antigen. The data indicate that only sIg  + BCL1 
cells are sensitive to lysis, whereas IgG-, IgM-, IgD-, and IgA-secreting myeloma cells, 
which have been reported to express low amounts of sIg (22), are negative. 
Sensitivity  of Splenic B  and  T  Cell Lymphoblasts  to Anti-Ig H  Effector Cells.  The previous 
data indicate that not all tissues of BALB/c origin express detectable quantities of the 
antigenic determinants recognized by C.B-20 anti-BALB/c effector cells. Therefore, 
experiments were performed to ascertain whether splenic T  and B cell lymphoblasts 
were equally sensitive to lysis. 
The data  in Table VII indicate that  both splenic  LPS and Con A  lymphoblasts 
were sensitive to  lysis by anti-Ig H  region  effector cells,  although  LPS blasts were 
usually  more sensitive than  Con  A  blasts.  Because splenic  Con  A  blasts contain  a 
considerable portion of Ig  ÷ cells and splenic LPS blasts contain a considerable portion 
of Ig- cells, we purified T  and B cells from spleens and then cultured each with either 
Con A  or LPS,  respectively. These populations of T  and  B  cell lymphoblasts were 
enriched for the appropriate cells and showed relatively little cross contamination (see 
footnotes to Table VI). When these cells were tested for their sensitivity to lysis, it was 
noted  that  the  LPS-stimulated  B  lymphoblasts were usually more sensitive to lysis 
than  the  LPS-stimulated  splenic  lymphoblasts,  whereas  the  Con  A-stimulated  T 
lymphoblasts dislayed little or no sensitivity to lysis. It should also be noted that the 
four types of target cells tested were equally sensitive to lysis by anti-H-2 effector cells 
(B 10.Q anti-BALB/c). 
Therefore, these data  indicate that  the target antigen(s)  recognized by anti-Ig H 
region effector cells have a restricted tissue distribution that appears to be coincident 
with the expression of sIg. 
TABLE VI 
Tumor Cell Typing for  Target Antigen 
Tumor  Genotype  Myeloma  protein  Target antigen 
allotype 
BCL1  Ig-I a  Ig6  a  + 
BCL1 X63  Ig-I a  Ig6  a, Ig4  a  - 
MOPC 315  Ig-la/Ig-I b  Ig2  a 
MOPC 300  Ig-l"/Ig-I b  Ig4  b 
MOPC 245  Ig-l"/Ig.l b  Ig4  b 
MOPC 104E  Ig-l"  Ig6  a  - 
TEPC 183  Ig-l"  Ig6 •  - 
TEPC 15  Ig-I a  Ig2"  - 
TEPC 1033  Ig-l"  Ig5"  - 
X63  Ig-I '~  Ig4  a  - 
P1798  Ig- l"  -  - 1364  CYTOTOXIC  T  CELLS  SPECIFIC  FOR  Ig  +  CELLS 
TABLE VII 
Sensitivity of Splenic Lymphoblasts to Anti-Ig H Effector Cells 
Cells  Net release at E:T =  100:1 
Mitogen  Experi-  Experi-  Experi-  Experi- 
Effectors  Targets 
ment  1  merit 2  ment 3  merit 4 
C.B-20 anti-BALB/c  BALB/c  WS  LPS  16.1"  25.3 (42.1)~:  --  -- 
WS  Con A  14.8§  7.6 (41.9)  --  -- 
BALB/c  B cells  LPS  20.211  17.8 (42.7)  35.8  -- 
T  cells  Con A  8.8¶  7.3 (39.0)  0.8  -- 
BALB/c anti-C.B-20  C.B-20  WS  LPS  --  --  --  20.0* 
WS  Con A  --  --  --  15.0§ 
C.B-20  B cells  LPS  --  --  --  29.51[ 
T  cells  Con A  --  --  --  8.7¶ 
* WS,  whole spleen;  whole spleen  LPS  lymphoblasts contained  68-77%  Ig  ÷  cells and  15-18%  Thy-l.2 + 
cells. 
:]: Numbers in parentheses represent lysis from target cells by B 10.Q anti-BALB/c effector cells. 
§ Whole spleen Con A  lymphoblasts contained  19-24% Ig  ÷ cells and 55-64% Thy-l.2 + cells. 
[[  B cell lymphoblasts contained 85-95% Ig  + cells and 2-7% Thy-l.2 + cells. 
¶ T  cell lymphoblasts contained  12-14% Ig  + cells and 75-78% Thy-l.2 + cells. 
Discussion 
The data in this report provide the first direct evidence for the existence of CTL 
specific  for  antigenic  determinants  expressed  on  sIg  +  cells.  The  target  antigens 
recognized by these CTL are encoded for by genes either linked to or identical with 
Ig H  chain loci. Furthermore, because C.B-20 anti-BALB/c effector cells do not lyse 
BAB-14 lymphoblasts, the antigen recognized on BALB/c targets is encoded for by a 
gene  linked  to  the  C  rather  than  the  V region  of the  Ig-1  locus.  Thus,  our  data 
demonstrate that the target antigens detected by the cytotoxic effector cells generated 
in  this system are  expressed on  LPS-induced B  cell lymphoblasts but  not  Con  A- 
induced T  cell lymphoblasts or a  T  cell leukemia. Although this indicates that  the 
target antigens are expressed on cells of the B and not the T cell lineage, these antigens 
are not expressed on all cells of B cell origin. We were unable to detect target antigens 
on  several  myeloma  cell  lines  that  have  been  reported  to  have  low  levels  of sIg 
(reviewed in 22). On the other hand, BCL1, an sIg  + B cell leukemia was sensitive to 
lysis.  Furthermore, a  BCLa ×  X63 hybridoma line that  secretes the same IgM as is 
expressed on the surface of the parental BCL1 line, but displays almost no sIg, was not 
lysed by the anti-Ig H effector cells. Taken together, these data suggest that the target 
antigen  being  detected  by  the  CTL  is  either  sIg  itself or  a  determinant  that  is 
coordinately expressed on Ig  + B cells. 
These data  provide a  possible  mechanism  whereby CTL could  regulate  B  cells 
expressing cell membrane allotypic (Ig)  determinants. This type of activity would be 
consistent with previous studies  indicating that other subpopulations of T  lympho- 
cytes, viz., helper and suppressor T  cells, can regulate the growth and differentiation 
of B cells possessing idiotypic or allotypic determinants on their membrane Ig. Thus, 
Herzenberg et al. (23, 24) have demonstrated allotype specific helper and suppressor 
T  cells.  Eichmann (25), Woodland and Cantor (26), and Bottomly and Maurer (27), 
have described helper cells that are idiotype specific. Rosenberg and Chiller (28) have 
evidence for an allotype (C region)-specific helper cell involved in the regulation of 
IgG responses. Both L'age-Stehr (29)  and Nutt et al.  (30)  have data to indicate that JAMES FORMAN, RICHARD CIAVARRA, AND ELLEN S. VITETTA  1365 
antigen-primed  B  cells  induce  the  expansion  of helper  T  cell  populations  that 
recognize allotypes or idiotypes on B cells. 
Rolink et al.  (11)  reported that CTL could be generated using allotype congenic 
strains  that  were similar but  not  identical to those used in this study. The effector 
cells they described detected an antigen expressed on a T  cell tumor as well as both 
T  and B cell lymphoblasts. In contrast, the antigen recognized by the cytotoxic cells 
generated here were restricted to sIg  + B cells. This discrepancy between the two sets 
of data could be due to the fact that the BALB/c animals used by Rolink et al. (11) 
may differ at an/g-linked H-antigen locus from the BALB/c line used to derive the 
allotype congenic strains. Accordingly, the CTL generated by Rolink et al. (1 l) might 
be specific for such an H  antigen(s). Alternatively, their culture system may allow for 
the generation of clones of effector cells that  recognize additional non-Ig antigenic 
determinants on lymphoid cells. In this regard, we have noted that in some experi- 
ments where CTL from individual animals were tested on P815 (Ig-1 c, H-2 a) target 
cells, that some C.B-20 anti-BALB/c effector cells lysed this cell line. The activity of 
the CTL from these mice may be similar to that described by Rolink et al. (11)  and 
is also consistent with the data of Riblet et al.  (31), who demonstrated that allotype 
congenic strains reject skin grafts. Thus, those antigens might be analogous to minor 
H  antigens  that  have been shown  to elicit both skin  graft  rejection and  to induce 
cytotoxie effeetor T  cell activity  (32).  However, it  is  also  possible  that  P815  cells 
express the same antigen  that  is detected on the sIg  + cells.  In  this case, the target 
antigen would most likely be a differentiation antigen with coordinate expression on 
sIg  + cells and P815 cells. 
There are several molecules in addition to CTL target antigens that are controlled 
by Ig-1  linked loci. For example, Owen et al. (33) have immunized BALB/c animals 
with cells from allotype congenic cells C.AL-20 mice and were able to produce an 
antiserum that recognized a molecule found on Lyt-2  + suppressor cells.  A hybridoma 
antibody that recognizes a second Ig-H-encoded  antigen expressed on Lyt-1  ÷ suppres- 
sor  inducer  cells  has  been  described  (G.  M.  Spurll  and  F.  L.  Owen,  personal 
communication).  A.  Finnegan  and  F.  L.  Owen  (personal  communication)  have 
produced a  C.B-20 anti-BALB/c antiserum that detects an antigen controlled by a 
gene linked to the  V region of Ig-H and is expressed on CTL. 
The  role  of cytotoxic  and  suppressor  T  cells  in  controlling  growth  of B  cell 
neoplasms is not clear. Bosma and  Bosma (34)  have shown  that  anti-allotype sup- 
pressor cells can regulate the secretion of Ig by myeloma cells from Ig-1 b mice. Rohrer 
and Lynch (35)  have demonstrated that suppression or enhancement of MOPC  315 
tumor cell growth, myeloma stem cell production, and IgA secretion can be influenced 
by carrier-specific helper or suppressor T  cells.  Flood et al.  (36)  have demonstrated 
that  mice immunized with  purified myeloma proteins  generate idiotype-specific T 
cells that regulate MOPC 315 growth. 
Abbas  et  al.  (4)  have  reported  that  Lyt-2  +,  cyclophosphamide- and  radiation- 
resistant T  cells can regulate Ig secretion by MOPC 315 cells in vitro. The criterion 
for defining these cytotoxic cells was based on these phenotypic characteristics and by 
their ability to reduce the viability of the tumor cells over a  2-3-d culture period. 
However, these effector cells did not cause direct lysis of target cells in a 4-h chromium 
release assay. Further, unlike the specificity of the CTL described in this report, these 1366  CYTOTOXIC  T  CELLS  SPECIFIC  FOR  Ig  ÷ CELLS 
cells were specific for the epitope which the MOPC  315 cells bind  (trinitrophenol) 
rather than the Ig itself. 
Although CTL could play a  role in  preventing B  cell tumors,  they may not  be 
relevant in regulating myeloma cell growth because the level of surface Ig on these 
cells is relatively small  (22).  On the other hand, tumor cells such as BCL1 may be 
more amenable to regulation by CTL because these cells generally have a high density 
of sIg (2), which could be recognized as a tumor-specific antigen. 
It is not  known whether the ability of C.B-20 mice to resist  BCL1 is  due to the 
activity of CTL. We previously reported (3) that the tumor rejection antigen maps to 
the  V region rather than the C region of the Ig gene complex because BAB-14 mice 
were tumor susceptible. However, recent data (R. Ciavarra and J.  Forman, unpub- 
lished  data)  suggest  that  for tumor rejection to occur, mice need to recognize two 
determinants, one in the V region and the other in the C region. A similar conclusion 
has been drawn  in the anti-Qa-1  CTL system (37).  If this interpretation is correct, 
then the anti-allotype CTL described here could be relevant anti-tumor effector cells.  2 
Summary 
C.B-20 mice were immunized with splenocytes or B leukemia cells (BCL1) from Ig 
H  chain  allotype congenic strains.  Spleen  cells  from  these  immunized  mice  were 
rechallenged in vitro to generate H-2-restricted cytotoxic T  cells that were specific for 
target antigens controlled by genes linked to the Ig H  chain locus. 
The anti-Ig H cytotoxic T  cells detected an antigen(s) expressed only on surface Ig  ~- 
cells.  Thus,  T  cell  lymphoblasts,  eight  BALB/c  myeloma cell  lines,  and  a  T  cell 
lymphoma were not lysed by the effector cells.  In contrast, B cell lymphoblasts and 
the surface Ig  + BCL1 cells were sensitive to lysis.  A  surface Ig-  hybridoma  (which 
secretes the IgM from the BCL1 cells) generated by fusing BCL1 cells to X63 myeloma 
cells was not killed by the effector cells. 
These data indicate that  cytotoxic T  cells specific for antigenic determinants on 
either surface IgM or IgD or on a molecule that is coordinately expressed on IgM + or 
IgD  + cells can be generated and that such cells might play a  role in regulating the 
growth of normal B cells or surface Ig  ÷ tumor cells in vivo. 
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